Amgen (AMGN) has seen a diverse range of market reactions recently. The biotech giant has consistently outpaced stock market gains, while dealing with legal hurdles such as the Sagebrush
340B lawsuit. Despite being downgraded amid competitive pressures, various entities including Y Intercept, UniSuper Management, and UBS have increased their stake, reflecting growing confidence in the company. Amgen's stake in harnessing
GLP-1 therapies for obesity is also noteworthy. The company has shown strong valuation momentum post Q3 results, driven by an impressive pipeline. As an example, its new cholesterol drug is considered very impactful. A significant recent development is the acquisition of Dark Blue Therapeutics, bolstering Amgen's oncology pipeline. The investment activity coupled with the potential market of its DISCO Oncology Deal and Maritide obesity compound, suggests a strong outlook. The company is also investing heavily in new facilities, including a $650M expansion in Puerto Rico. This, coupled with favorable price targets set by firms like DBS and Goldman Sachs, and Amgen's continuous dividend growth suggests this bio-tech giant will continue being a preferred stock for income investors.
Amgen AMGN News Analytics from Fri, 18 Jul 2025 07:00:00 GMT to Sat, 24 Jan 2026 16:30:00 GMT -
Rating 8
- Innovation 8
- Rumor -6
